These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31745645)

  • 1. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
    Kind S; Büscheck F; Höflmayer D; Hube-Magg C; Kluth M; Tsourlakis MC; Steurer S; Clauditz TS; Luebke AM; Burandt E; Wilczak W; Hinsch A; Dum D; Weidemann S; Fraune C; Beyer B; Steuber T; Huland H; Graefen M; Fisch M; Simon R; Sauter G; Schlomm T; Minner S; Eichenauer T
    World J Urol; 2020 Sep; 38(9):2185-2196. PubMed ID: 31745645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
    Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
    Eichenauer T; Federlein F; Möller K; Chirico V; Kind S; Lennartz M; Lutz F; Hube-Magg C; Höflmayer D; Fisch M; Huland H; Heinzer H; Graefen M; Haese A; Schroeder C; Lebok P; Minner S; Simon R; Sauter G; Schlomm T; Wilczak W; Steurer S; Luebke AM
    Pathology; 2020 Jun; 52(4):421-430. PubMed ID: 32317175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
    Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
    Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
    BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
    Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
    Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
    Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
    Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
    Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
    Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
    Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
    Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
    Heinrich MC; Göbel C; Kluth M; Bernreuther C; Sauer C; Schroeder C; Möller-Koop C; Hube-Magg C; Lebok P; Burandt E; Sauter G; Simon R; Huland H; Graefen M; Heinzer H; Schlomm T; Heumann A
    BMC Cancer; 2018 May; 18(1):612. PubMed ID: 29855276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.